EvoNext Holdings

EvoNext is a biotechnology company specializing in the development of next-generation extracellular vesicle (EV) therapeutics. The company utilizes a proprietary platform to engineer red blood cell-derived EVs (RBCEVs) for the targeted delivery of diverse payloads, including antisense oligonucleotides, mRNA, and small molecules. By leveraging the natural biocompatibility and low immunogenicity of red blood cells, EvoNext aims to overcome traditional drug delivery challenges such as toxicity and limited tissue penetration. Their technology allows for scalable, high-purity production of EVs, positioning the company as a leader in the emerging field of exosome-based medicine for oncology and rare genetic disorders.